Ask the expert: How will Brexit affect Parkinson’s drugs and research?
Author: Simge Eva DoganPublished: 30 January 2020
Prep: Cook: Serves:
The UK is due to
formally leave the European Union this week. In the second in our series where
we ask experts about the biggest issues facing the Parkinson’s community, Dr
Kieran Breen of the European Medicines Agency Committee for Advanced Therapies gives
his views on the likely impact of Brexit – from the availability of Parkinson’s
medication to international research collaboration
First of all, could you explain to our readers how
Brexit might affect people with Parkinson’s? Will there be an impact on the
supply of medications?
It’s very difficult to look into the future, but yes, the
availability of the therapies and drugs for people with Parkinson’s may be
impacted. We don’t know how things are going to develop in the transition period
over the next 11 months, but it could be that when drugs are coming through
customs they are delayed at the point of entry to the country.
I would imagine that because pharmaceuticals are so
important to the lives of people in the UK with Parkinson’s and every other
condition, that the manufacturing standards are going to stay the same here as
with the rest of Europe.
What might happen to Parkinson’s drugs manufacturing in
At the moment, within Europe, the quality of drug
manufacture is the same throughout the 28 countries. The manufacturing is
usually assessed at a local level, so in the UK that would be the Medicines and
Healthcare products Regulatory Agency (MHRA), which is responsible for drug
If the MHRA assess and approve a drug at a manufacturing
site, it can go anywhere to 28 countries. However, come Brexit, what will
happen is that will no longer be the case. Any drugs manufactured in the UK
cannot automatically be sent to the 27 countries and vice versa.
Theoretically what would happen in the case of a hard Brexit is somebody from the UK will have to go to wherever the drug is manufactured and assess the quality of the manufacturing process. It’s unlikely that this will happen, but it’s a possibility.
Will Brexit impact Parkinson’s drug trials?
Once the UK is no longer in the EU, it will be less likely
that drug trials will be carried out in the UK, because the agreed standards may
be different. Also, if companies want to license a new drug, will they submit
the marketing authorisation application to the European Medicines Agency (EMA),
which is around 600 million people, or submit it to the UK, which is 60 million
people? Well, it’s a no brainer that companies are more likely to submit to the
EU funding supports a substantial amount of medical research in the UK. What effect do you think that Brexit will have for the future of Parkinson’s research and innovation in the UK?
There are two sources of funding
in the UK for Parkinson’s research – charity funding and government funding.
With government funding you can never tell what’s going to come up by the next
budget, but UK charities will continue to fund research. I don’t think Brexit
will have a significant impact on that.
The main area where there is
going to be a problem is European research funding. The European Commission
I don’t know off-hand how much of that goes to Parkinson’s.
Once Brexit happens, UK
researchers will no longer have access to EU funding, so it will choke off the
finance but it will also provide a barrier to international interaction. Interacting
with other people and exchanging ideas is a really important part of research. International
collaboration facilitates the development of new therapies, treatments,
diagnostic models and really increases the understanding of Parkinson’s.
What’s your advice for people in the Parkinson’s
community wondering how best to prepare for these changes?
With Brexit, who knows what’s going to happen? Patient organisations and patients’ collaborators need to
keep a very close eye on what’s happening from a Brexit perspective and make
sure they are talking to the right people so that their voices are heard.
Patients and healthcare professionals need to work with organisations to make sure that the agenda is moved forward – and make sure that MPs are aware of the implications of Brexit from a patient’s perspective. It’s really important that the topic of drug availability remains on the agenda.
Need to know: Dr Kieran Breen is a UK-based pharmacologist. He worked at Parkinson’s UK for nine years as Director of Research & Innovation. He was nominated by the EPDA to join the European Medicines Agency Committee for Advanced Therapies in 2013 – a group which deals with the next generation of therapies.
At a glance: Parkinson’s and Brexit
Brexit may affect the availability of Parkinson’s therapies and drugs in the UK.
It will be less likely that drug trials are carried out in the UK after Brexit.
After Brexit, UK researchers will no longer have access to EU funding which may affect both the financing of new studies and international collaboration.
Parkinson’s organisations need to make sure that patient voices are heard during the transition and lobby the government to ensure that drug availability remains on the agenda.
Telemedicine: how Sweden is reducing waiting times for Parkinson’s treatment
Video calling tech is speeding up access to advanced treatment
1 day ago
Researchers “stunned” by study that raises hopes for Parkinson’s treatment
A new study reprogramming cells to replace reduced dopamine neurons in the brain could be used to reverse symptoms of Parkinson’s and other neurological conditions. As part of the study – conducted by the University of California San Diego (UCSD) – researchers found a way to convert star-shaped brain cells called astrocytes into cells producing dopamine. The team used the method to treat mouse models of Parkinson’s, administering the treatment into the areas of the brain that typically lose dopamine producing neurons. This restored reduced dopamine production to normal levels and reversed the symptoms of Parkinson’s. The researchers will continue to optimise the therapy in other mouse models of Parkinson’s before testing it on people with the condition. William Mobley, a neurosciences professor at UCSD, said: “I was stunned at what I saw. This whole new strategy for treating neurodegeneration gives hope that it may be possible to help even…
Could a magnetically powered implant treat Parkinson’s tremors?
A tiny surgical implant about the size of a grain of rice that can be implanted with minimally invasive surgery may be used to treat tremors in people with Parkinson’s. Developed by a team of researchers at Rice University, US, the implant uses a thin film of magnetoelectric material to convert acoustic waves from the brain’s magnetic field into electrical voltage. The device produces the same high-frequency signals as clinically approved implants used to treat Parkinson’s, epilepsy and other conditions – and eliminates the need for battery or wired power supply. In an initial study, the researchers showed that the implants worked in rodents. Professor Jacob Robinson, corresponding author of the study, said: “Our results suggest that using magnetoelectric materials for wireless power delivery is more than a novel idea. These materials are excellent candidates for clinical-grade, wireless bioelectronics.”
What do you think of Parkinson’s Life? Take part in our reader survey
We’re always looking to improve our readers’ experience of the Parkinson’s Life magazine, newsletter and podcast. That’s why we’ve launched a new survey to give our international community of readers a chance to share their views and influence what we do. The survey takes just 10 minutes to complete – and, as a little ‘thank you’ for taking part, readers will be entered into a competition to win a £50 Amazon voucher. Readers will also have the chance to share interest in joining our future reader panel and take part in regular surveys and discussions to help us to deliver the best content to our international community. Ready to tell us what you think of Parkinson’s Life? Take part in the reader survey here.